OFI Invest Asset Management Raises Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• OFI Invest Asset Management increased its stake in Thermo Fisher Scientific Inc. by 57.9% during the second quarter, now owning 108,377 shares valued at approximately $43.9 million.
• Several large investors made significant moves in TMO, with Nuveen LLC purchasing a new stake of about $532 million in the first quarter, showcasing strong institutional interest.
• After beating analysts' earnings expectations for Q2, Thermo Fisher Scientific reported a 2.9% increase in revenue year-over-year, forecasting Q3 2025 EPS guidance of $5.460 to $5.510.

OFI Invest Asset Management increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 57.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 108,377 shares of the medical research company's stock after purchasing an additional 39,752 shares during the quarter. OFI Invest Asset Management's holdings in Thermo Fisher Scientific were worth $43,943,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in TMO. Nuveen LLC purchased a new stake in shares of Thermo Fisher Scientific during the first quarter worth approximately $532,360,000. EdgePoint Investment Group Inc. purchased a new stake in shares of Thermo Fisher Scientific during the first quarter worth approximately $172,139,000. Cohen Investment Advisors LLC increased its position in shares of Thermo Fisher Scientific by 6,655.5% during the first quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company's stock worth $167,271,000 after purchasing an additional 331,180 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Thermo Fisher Scientific by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock worth $1,368,859,000 after acquiring an additional 329,974 shares during the last quarter. Finally, Auto Owners Insurance Co increased its stake in shares of Thermo Fisher Scientific by 6,773.5% in the 1st quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company's stock worth $143,309,000 after acquiring an additional 283,810 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $524.95 on Friday. The stock has a fifty day simple moving average of $488.68 and a 200-day simple moving average of $447.94. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The stock has a market cap of $198.23 billion, a PE ratio of 30.36, a P/E/G ratio of 2.85 and a beta of 0.77. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same period last year, the business posted $5.37 EPS. Thermo Fisher Scientific's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on TMO shares. Hsbc Global Res downgraded Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Wells Fargo & Company cut their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research note on Thursday, July 24th. Redburn Partners set a $580.00 target price on Thermo Fisher Scientific in a research note on Wednesday. Barclays raised their target price on Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an "overweight" rating in a research note on Thursday, October 2nd. Finally, HSBC reiterated a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and an average price target of $593.43.

Insider Activity at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock worth $14,182,963 in the last three months. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.